Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

RADNOR, Pa. , Aug. 21, 2024 /PRNewswire/ -- law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").

Dexcom Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

DexCom, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by DexCom (DXCM)

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM LEGAL UPDATE: Lose Money on Your DexCom, Inc. Investment? Investors are Alerted of Securities Fraud Class Action Investigation and Urged to Contact BFA Law (NASDAQ:DXCM)

CrowdStrike

July saw the market retreat quite a bit from its height in mid-July. DexCom's outlook disappointed investors -- and the caution may be warranted.

Is It Time to Buy July's Worst-Performing S&P 500 Stocks?

Insulet

Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.

These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

DXCM ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by DexCom, Inc.

An Investigation Has Commenced on Behalf of DexCom, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your DXCM Losses.

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Invited By The Schall Law Firm To Participate In The Securities Fraud Investigation Of DexCom Inc

DXCM STOCK ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of an Ongoing Investigation

RADNOR, PA / ACCESSWIRE / August 20, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.

DXCM Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm

Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about Securities Fraud Investigation - DXCM

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM STOCK ALERT: Suffer Losses on Your DexCom, Inc. Investment? Investors are Encouraged to Contact BFA Law about its Securities Fraud Class Action Investigation (NASDAQ:DXCM)

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

DexCom, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - DXCM

DexCom, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- DXCM

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM)

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Urged By The Schall Law Firm To Join The DexCom Inc Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders To Join DexCom Inc Securities Fraud Investigation

Novartis

Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.

2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200

Opendoor

These discounted stocks are contending with dynamic market environments. DexCom has had a bad reaction from investors after its recent earnings, but a closer look is warranted.

2 Growth Stocks to Buy at a Discount

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTMENT NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors that Lost Money are Encouraged to Contact BFA Law about its Investigation (NASDAQ:DXCM)

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Seeks Shareholders To Partake In DexCom Inc Securities Fraud Investigation

The Schall Law Firm Seeks Investors To Partake In DexCom Inc Securities Fraud Investigation

RADNOR, PA / ACCESSWIRE / August 17, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.

DexCom Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm

News for DexCom Stock (DXCM)